Cardiovascular disease prevention using fixed dose pharmacotherapy in Iran: Updated meta-analyses and mortality estimation

Archives of Iranian Medicine

Volumn 15, Issue 9, 2012, Pages 531-537

  Sepanlou, Sadaf G ^a   Farzadfar, Farshad ^b   Jafari, Elham ^a   Danaei, Goodarz ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cardiovasculardiseases; Drug combinations; Polypill; Primary prevention; Riskfactors

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CARDIOVASCULAR AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; THIAZIDE DIURETIC AGENT;

ARTICLE; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; EFFECT SIZE; GASTROINTESTINAL HEMORRHAGE; HUMAN; IRAN; ISCHEMIC HEART DISEASE; LOW FAT DIET; META ANALYSIS; PILL; POLYPILL; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; STROKE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ASPIRIN; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IRAN; MIDDLE AGED; MODELS, STATISTICAL; MYOCARDIAL ISCHEMIA; RISK; STROKE; THIAZIDES; TREATMENT OUTCOME;

EID: 84866050103     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Global status report on noncommunicable diseases 2010. World Health Organization. Geneva: 2011.
2. Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 2009; 6(4): 1000058.
3. Ford ES, Capewell S. Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates. J Am Coll Cardiol. 2007; 50(22): 2128-2132.
4. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA. 2005; 294(10): 1255-1259.
5. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR Kottke TE, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007; 356(23): 2388-2398.
6. Goldman L, Phillips KA, Coxson P, Goldman PA, Williams L, Hunink MG, et al. The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost. J Am Coll Cardiol. 2001; 38(4): 1012-1017.
7. Young F, Capewell S, Ford ES, Critchley JA. Coronary mortality declines in the U.S. between 1980 and 2000 quantifying the contributions from primary and secondary prevention. Am JPrevMed. 2010; 39(3): 228-234.
8. Capewell S, Hayes DK, Ford ES, Critchley JA, Croft JB, Greenlund KJ, et al. Life-years gained among US adults from modern treatments and changes in the prevalence of 6 coronary heart disease risk factors between 1980 and 2000. Am J Epidemiol. 2009; 170(2): 229-236.
9. Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, Pa-ciorek CJ, et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet. 2011; 377(9765): 578-586.
10. Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet. 2011; 377(9765): 568-577.
11. World Health Organization. Secondary Prevention of Noncommunica-ble Diseases in Low and Middle Income Countries Through Community-based and Health Service Intervention. Wellcome Trust meeting report 1-3 August. World Health Organization. Geneva: 2001.
12. The World Health Report 2002. Reducing risks, promoting healthy life. World Health Organization. Geneva: 2002.
13. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003; 326(7404): 1419.
14. Malekzadeh F, Marshall T, Pourshams A, Gharravi M, Aslani A, Nat-eghi A, et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. Int J Clin Pract. 2010; 64(9): 1220-1227.
15. Rodgers A, Patel A, Berwanger O, Bots M, Grimm R, Grobbee DE, et al. An international randomised placebo-controlled trial of a four-component combination pill (polypill) in people with raised cardiovascular risk. PLoS One. 2011; 6(5):19857.
16. Yusuf S, Pais P, Afzal R Xavier D, Teo K, Eikelboom J, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomized trial. Lancet. 2009; 373(9672): 1341-1351.
17. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195-2207.
18. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005; 352(13): 1293-1304.
19. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009; 338: 1665.
20. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329): 71-86.
21. Danaei G, Tavakkoli M, Hernan MA, Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol. 2012; 175(4):250-262.
22. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Institutes of Health. 2004.
23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3): 177-188.
24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-634.
25. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003; 326(7404): 1427.
26. Harris RJ, Bradburn MJ, Deeks JJ, Harbord RM, Altman DG, Sterne JAC. Metan: fixedand random-effects meta-analysis. Stata J. 2008; 8(1): 3-28.
27. Khosravi A, Taylor R, Naghavi M, Lopez AD. Mortality in the Islamic Republic of Iran, 1964-2004. Bull World Health Organ. 2007; 85(8):607-614.
28. Farzadfar F, Danaei G, Namdaritabar H, Rajaratnam JK, Marcus JR, Khosravi A, et al. National and subnational mortality effects of metabolic risk factors and smoking in Iran: a comparative risk assessment. PopulHealthMetr. 2011;9(1):55.
29. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002; 325(7374): 1202.
30. Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. EurHeartJ. 2009; 30(1): 6-15.
31. Tolman KG. The liver and lovastatin. Am J Cardiol. 2002; 89(12): 1374-1380.
32. Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroen-terol. 2010; 105(5): 978-980.
33. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010; 121(9): 1069-1077.
34. Floyd JS, Heckbert SR, Weiss NS, Carrell DS, Psaty BM. Use of administrative data to estimate the incidence of statin-related rhabdomy-olysis. JAMA. 2012; 307(15):1580-1582.
35. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003; 289(13): 1681-1690.
36. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011; 305(24):2556-2564.
37. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010; 375(9716): 735-742.
38. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet. 2006; 368(9536):679-686.
39. Lim SS, Gaziano TA, Gakidou E, Reddy KS, Farzadfar F, Lozano R, et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet. 2007; 370(9604):2054-2062.